Pomalidomide 4'-PEG5-acid is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapies. Its structure allows it to act as a linker, connecting cytotoxic agents to monoclonal antibodies, ensuring precise delivery of the drug to cancer cells while minimizing damage to healthy tissues. This targeted approach enhances the efficacy of cancer treatments and reduces systemic side effects. Additionally, the PEG (polyethylene glycol) moiety in the molecule improves solubility and stability, making it more suitable for therapeutic formulations. Its application is particularly significant in treating hematologic malignancies and solid tumors, where precision medicine is crucial.